Condition
Recurrent Meningioma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Recurrent Meningioma clinical trials that are recruiting, at sites in 7 countries (most in United States (4), Austria (1), France (1)). By phase: Phase 2 (3), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 7Countries
Newest Recurrent Meningioma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| RYZ101 (225Ac-DOTATATE) for progressive or recurrent intracranial meningioma | Phase 1/2 | Columbus, Ohio | Recruiting | Sep 2, 2025 |
| Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma | — | San Francisco, California | Recruiting | Aug 16, 2024 |
| Using 177Lu-DOTATATE to treat recurrent meningioma | Phase 2 | Innsbruck and 18 other locations | Recruiting | Mar 22, 2024 |
| Using Lutathera to treat inoperable, progressive meningioma after radiation therapy | Phase 2 | Rochester, Minnesota | Recruiting | Sep 9, 2019 |
| Treating progressive meningiomas with targeted therapies | Phase 2 | Birmingham, Alabama and 790 other locations | Recruiting | Aug 14, 2015 |
All recruiting trials (5)
-
RYZ101 (225Ac-DOTATATE) for progressive or recurrent intracranial meningioma
This trial tests whether RYZ101, a radiopharmaceutical, can help people with growing or returning brain meningiomas that express somatostatin receptors.
-
Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
This study is testing a new way of giving radiation therapy over five days to see if it helps people with certain types of brain tumors feel better and have a better quality of life after treatment.
-
Using 177Lu-DOTATATE to treat recurrent meningioma
This study is testing if a new targeted treatment called 177Lu-DOTATATE can help people with recurrent meningioma who haven't had success with regular treatments like surgery and radiation.
-
Using Lutathera to treat inoperable, progressive meningioma after radiation therapy
This study is testing if a radioactive drug called Lutathera can help people with inoperable and progressive meningiomas feel better after they've had radiation therapy.
-
Treating progressive meningiomas with targeted therapies
This study is testing if new targeted therapies can help people with progressive meningiomas who have certain genetic mutations feel better and live longer.
Related topics
Quick answers
How many Recurrent Meningioma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 7 countries. The most sites are in United States (4 trials), Austria (1 trial), France (1 trial), Germany (1 trial), Norway (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.